In order to deliver cell-based therapies on a commercial scale, cell therapy companies and suppliers must form partnerships in order to overcome existing manufacturing, regulatory, and analytical challenges. Four leading cell therapy experts discuss what is and what has to be done in order to accomplish this objective.
Jon Rowley, Innovation Director, Cell Processing Technologies, Lonza
Chris Mason, Professor, University College London
Robert Speziale, Vice President, Business Development, Invetech
Barry Rosenblatt, President, SME Biotech Consulting